SiBone (NASDAQ:SIBN – Get Free Report) has been assigned an average rating of “Moderate Buy” from the seven analysts that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating on the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $24.1667.
SIBN has been the topic of a number of research analyst reports. UBS Group upped their target price on SiBone from $24.00 to $25.00 and gave the stock a “buy” rating in a research note on Tuesday, August 4th. Truist Financial restated a “buy” rating and issued a $23.00 price objective (up from $21.00) on shares of SiBone in a research report on Tuesday, August 4th. Weiss Ratings raised shares of SiBone from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 20th. Finally, TD Cowen lifted their target price on shares of SiBone from $18.00 to $20.00 and gave the company a “buy” rating in a research report on Tuesday, August 4th.
Check Out Our Latest Research Report on SiBone
SiBone Price Performance
SiBone (NASDAQ:SIBN – Get Free Report) last announced its quarterly earnings results on Monday, August 3rd. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.06. The firm had revenue of $56.01 million during the quarter, compared to the consensus estimate of $55.34 million. SiBone had a negative net margin of 6.85% and a negative return on equity of 8.23%. As a group, sell-side analysts predict that SiBone will post -0.4 earnings per share for the current fiscal year.
Insider Activity at SiBone
In related news, SVP Michael A. Pisetsky sold 3,725 shares of the company’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $18.63, for a total value of $69,396.75. Following the completion of the transaction, the senior vice president directly owned 273,650 shares in the company, valued at approximately $5,098,099.50. The trade was a 1.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Anshul Maheshwari sold 11,636 shares of the firm’s stock in a transaction dated Monday, August 24th. The shares were sold at an average price of $20.11, for a total value of $233,999.96. Following the sale, the insider owned 223,284 shares in the company, valued at $4,490,241.24. The trade was a 4.95% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 165,231 shares of company stock worth $3,193,690 over the last quarter. 4.00% of the stock is currently owned by corporate insiders.
Hedge Funds Weigh In On SiBone
Several institutional investors have recently modified their holdings of SIBN. Royal Bank of Canada lifted its position in SiBone by 98.5% in the 4th quarter. Royal Bank of Canada now owns 1,483 shares of the company’s stock worth $29,000 after buying an additional 736 shares during the last quarter. Versant Capital Management Inc boosted its stake in SiBone by 102.9% in the second quarter. Versant Capital Management Inc now owns 1,749 shares of the company’s stock worth $29,000 after buying an additional 887 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in SiBone by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,426 shares of the company’s stock valued at $343,000 after acquiring an additional 1,053 shares during the last quarter. Larson Financial Group LLC grew its position in SiBone by 42.3% during the fourth quarter. Larson Financial Group LLC now owns 3,569 shares of the company’s stock valued at $70,000 after acquiring an additional 1,061 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD raised its stake in shares of SiBone by 4.1% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 37,159 shares of the company’s stock worth $733,000 after acquiring an additional 1,459 shares in the last quarter. 98.11% of the stock is currently owned by institutional investors.
About SiBone
Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.
FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.
See Also
- Five stocks we like better than SiBone
- 3 Under-the-Radar Defense Stocks With Record Backlogs
- This Korea ETF Has Soared, But the Rally May Not Be Over
- Why Guidewire’s Post-Earnings Plunge May Not Last
- Ride-Share Reckoning: Tesla Drives Into Uber’s Lane
Receive News & Ratings for SiBone Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SiBone and related companies with MarketBeat.com's FREE daily email newsletter.
